Abbvie Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ABBVIE, and what generic alternatives to ABBVIE drugs are available?
ABBVIE has one hundred and thirty-eight approved drugs.
There are two hundred and twenty-nine US patents protecting ABBVIE drugs.
There are two thousand seven hundred and twenty-one patent family members on ABBVIE drugs in sixty-six countries and three hundred and ninety-one supplementary protection certificates in nineteen countries.
Summary for Abbvie
International Patents: | 2721 |
US Patents: | 229 |
Tradenames: | 124 |
Ingredients: | 99 |
NDAs: | 138 |
Drug Master File Entries: | 1 |
Patent Litigation for Abbvie: | See patent lawsuits for Abbvie |
Drugs and US Patents for Abbvie
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie | DEPAKOTE | divalproex sodium | TABLET, DELAYED RELEASE;ORAL | 018723-001 | Mar 10, 1983 | AB | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Abbvie | VENCLEXTA | venetoclax | TABLET;ORAL | 208573-003 | Apr 11, 2016 | RX | Yes | Yes | 10,993,942 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Abbvie | VRAYLAR | cariprazine hydrochloride | CAPSULE;ORAL | 204370-004 | Sep 17, 2015 | RX | Yes | No | ⤷ Try a Trial | ⤷ Try a Trial | |||||
Abbvie | RINVOQ | upadacitinib | TABLET, EXTENDED RELEASE;ORAL | 211675-002 | Jan 14, 2022 | RX | Yes | No | 11,718,627 | ⤷ Try a Trial | Y | Y | ⤷ Try a Trial | ||
Abbvie | MAVYRET | glecaprevir; pibrentasvir | TABLET;ORAL | 209394-001 | Aug 3, 2017 | RX | Yes | Yes | 10,286,029*PED | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Abbvie
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-004 | Jul 28, 1997 | 6,129,930 | ⤷ Try a Trial |
Abbvie | OZURDEX | dexamethasone | IMPLANT;INTRAVITREAL | 022315-001 | Jun 17, 2009 | 9,592,242 | ⤷ Try a Trial |
Abbvie | CARAFATE | sucralfate | TABLET;ORAL | 018333-001 | Approved Prior to Jan 1, 1982 | 3,432,489 | ⤷ Try a Trial |
Abbvie | NORVIR | ritonavir | CAPSULE;ORAL | 020945-001 | Jun 29, 1999 | 6,232,333*PED | ⤷ Try a Trial |
Abbvie | OZURDEX | dexamethasone | IMPLANT;INTRAVITREAL | 022315-001 | Jun 17, 2009 | 9,192,511 | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Delayed-release Tablets | 800 mg | ➤ Subscribe | 2011-07-13 |
➤ Subscribe | Extended-release Capsules | 7 mg, 14 mg, 21 mg, and 28 mg | ➤ Subscribe | 2013-06-10 |
➤ Subscribe | Ophthalmic Solution | 0.40% | ➤ Subscribe | 2005-01-28 |
➤ Subscribe | Tablets | 10 mg, 20 mg, and 40 mg | ➤ Subscribe | 2015-01-21 |
➤ Subscribe | Extended-release Tablets | 250 mg | ➤ Subscribe | 2004-05-03 |
➤ Subscribe | Capsules | 21 mg/10 mg | ➤ Subscribe | 2016-09-23 |
➤ Subscribe | Opthalmic Solution | 0.45% | ➤ Subscribe | 2011-08-24 |
➤ Subscribe | Extended-release Tablets | 7.5 mg and 15 mg | ➤ Subscribe | 2008-12-22 |
➤ Subscribe | Tablets | 100 mg/25 mg | ➤ Subscribe | 2008-12-23 |
➤ Subscribe | Ophthalmic Solution | 0.15% | ➤ Subscribe | 2006-11-03 |
➤ Subscribe | Extended-release Tablets | 1 mg/240 mg | ➤ Subscribe | 2008-02-20 |
➤ Subscribe | Capsules | 145 mcg and 290 mcg | ➤ Subscribe | 2016-08-30 |
➤ Subscribe | Ophthalmic Solution | 0.25% | ➤ Subscribe | 2014-07-30 |
➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
➤ Subscribe | Tablets | 5 mg/80 mg | ➤ Subscribe | 2017-06-09 |
➤ Subscribe | Ophthalmic Solution | 0.01% | ➤ Subscribe | 2011-04-05 |
➤ Subscribe | Delayed-release Capsules | 400 mg | ➤ Subscribe | 2014-06-17 |
➤ Subscribe | Capsules | 1 mcg and 2 mcg | ➤ Subscribe | 2008-10-14 |
➤ Subscribe | Tablets | 5 mg and 10 mg | ➤ Subscribe | 2007-10-16 |
➤ Subscribe | Topical Solution | 0.03% | ➤ Subscribe | 2010-05-03 |
➤ Subscribe | Delayed-release Capsules | 135 mg | ➤ Subscribe | 2009-09-01 |
➤ Subscribe | Gel | 7.5% | ➤ Subscribe | 2017-02-13 |
➤ Subscribe | Tablets | 400 mg and 600 mg | ➤ Subscribe | 2010-05-10 |
➤ Subscribe | Capsules | 10 mg and 20 mg | ➤ Subscribe | 2005-03-30 |
➤ Subscribe | Extended-release Capsules | 7 mg, 14 mg, 21 mg, and 28 mg | ➤ Subscribe | 2013-08-16 |
➤ Subscribe | Injection | 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial | ➤ Subscribe | 2009-08-04 |
➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
➤ Subscribe | Suppository | 1000 mg | ➤ Subscribe | 2013-05-24 |
➤ Subscribe | Extended-release Capsules | 7 mg, 14 mg, 21 mg | ➤ Subscribe | 2013-06-17 |
➤ Subscribe | Injection | 400 mg/vial and 600 mg/vial | ➤ Subscribe | 2014-10-29 |
➤ Subscribe | Tablets | 5 mg/200 mg | ➤ Subscribe | 2005-05-27 |
➤ Subscribe | Extended-release Tablet | 500 mg | ➤ Subscribe | 2010-12-06 |
➤ Subscribe | Capsules | 14 mg/10 mg and 28 mg/10 mg | ➤ Subscribe | 2015-05-18 |
➤ Subscribe | Opthalmic Solution | 0.45% | ➤ Subscribe | 2011-08-23 |
➤ Subscribe | Extended-release Tablets | 500 mg | ➤ Subscribe | 2005-02-08 |
➤ Subscribe | Capsules | 7 mg/10 mg | ➤ Subscribe | 2016-09-26 |
➤ Subscribe | Ophthalmic Solution | 0.10% | ➤ Subscribe | 2006-12-20 |
➤ Subscribe | Extended-release Tablets | 2 mg/180 mg and 2 mg/240 mg | ➤ Subscribe | 2007-11-09 |
➤ Subscribe | Oral Solution | 80 mg/20 mg per mL | ➤ Subscribe | 2014-06-19 |
➤ Subscribe | Ophthalmic Solution | 0.2%/0.5% | ➤ Subscribe | 2008-11-21 |
➤ Subscribe | Extended-release Tablets | 4 mg/ 240 mg | ➤ Subscribe | 2007-07-24 |
➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
➤ Subscribe | Ophthalmic Solution | 0.03% | ➤ Subscribe | 2008-12-22 |
➤ Subscribe | Injection | 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials | ➤ Subscribe | 2008-11-28 |
➤ Subscribe | Tablets | 1 mg, 2 mg and 4 mg | ➤ Subscribe | 2004-10-04 |
➤ Subscribe | Ophthalmic Solution | 0.5% | ➤ Subscribe | 2010-12-07 |
➤ Subscribe | Delayed-release Capsules | 45 mg | ➤ Subscribe | 2009-09-02 |
➤ Subscribe | Capsules | 4 mcg | ➤ Subscribe | 2008-08-25 |
➤ Subscribe | Tablets | 12.5 mg, 25 mg, 50 mg, and 100 mg | ➤ Subscribe | 2013-01-14 |
➤ Subscribe | Capsules | 5 mg | ➤ Subscribe | 2005-08-17 |
➤ Subscribe | Extended-release Capsules | 20 mg, 40 mg, 80 mg and 120 mg | ➤ Subscribe | 2017-07-25 |
➤ Subscribe | Gel | 10% | ➤ Subscribe | 2014-06-19 |
➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
➤ Subscribe | Injection | 10 mg/mL (2 mL) | ➤ Subscribe | 2018-07-13 |
➤ Subscribe | Extended-release Capsules | 28 mg | ➤ Subscribe | 2013-06-12 |
➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2009-08-12 |
➤ Subscribe | Tablets | 2.5 mg/200 mg | ➤ Subscribe | 2006-02-24 |
International Patents for Abbvie Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 6808660 | ⤷ Try a Trial |
New Zealand | 588367 | ⤷ Try a Trial |
Japan | 5902187 | ⤷ Try a Trial |
Israel | 268976 | ⤷ Try a Trial |
Portugal | 1911763 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Abbvie Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2782584 | LUC00245 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: COMPOSITION CONTENANT A LA FOIS DE L'ESTRADIOL (17SS-ESTRADIOL), EVENTUELLEMENT SOUS FORME D'UN SEL, HYDRATE OU SOLVATE PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI (Y COMPRIS SOUS FORME HEMIHYDRATEE), ET DE LA PROGESTERONE; AUTHORISATION NUMBER AND DATE: BE582231 20210701 |
2692346 | 300901 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: PIBRENTASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/17/1213 20170728 |
2203431 | C02203431/01 | Switzerland | ⤷ Try a Trial | FORMER OWNER: ABBVIE BAHAMAS LIMITED, BS |
1631293 | C300683 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 |
1912999 | 1490062-5 | Sweden | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REG. NO/DATE: EU/1/14/924 20140516 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.